Atropos Health builds GENEVA OS™, an operating system that converts real-world clinical data into high-quality, personalized real-world evidence and offers vertical user experiences such as ChatRWD™. ChatRWD, launched in beta in Q4 2023, is a chat-based AI co-pilot that the company says cuts production time for publication-grade evidence from months to minutes while aiming to minimize hallucination risk. The platform has been adopted by healthcare institutions, data platforms, research institutions, and life sciences companies. The company positions its products as a trusted quality layer between healthcare data and clinical/research evidence, and aims to democratize access to real-world evidence to improve decision making and patient outcomes. With this funding, Atropos plans to expand its focus on value-based care, deepen vertical integrations (including oncology and specialty care), and scale automation and full launch of ChatRWD. Atropos Health develops GENEVA OS, a Generative Evidence Acceleration Operating System that powers the Atropos Evidence Network and analyzes de-identified medical records. The company says the network includes more than 160 million patients’ de-identified medical data and its new ChatRWD application delivers answers in minutes via natural-language queries and a chat interface. Atropos recently partnered with Google Cloud to optimize GENEVA OS for Google’s healthcare data tools, enabling datasets hosted in Google Cloud to join the Evidence Network seamlessly. The integration is intended to let health systems and pharmaceutical companies generate near-instant insights for use cases such as optimizing formularies, reducing length of stay, accelerating research, and supporting shared decision-making. Atropos emphasizes rigorous data privacy and security measures within Google Cloud’s infrastructure. Financially, the company said it raised an undisclosed strategic financing from Presidio Ventures, Samsung Next, and others to support expansion and its mission to close evidence gaps in medicine worldwide. Atropos Health is a Palo Alto–based developer of a physician consultation service that delivers research-grade real-world evidence at the point of care. The company uses millions of anonymized patient records to help providers answer clinical questions that have fallen through the cracks of the evidence-based literature. Led by newly appointed CEO Brigham Hyde, PhD, Atropos retains President Neil Sanghavi and CMO Dr. Saurabh Gombar, while co-founder Nigam Shah remains on the board. The company will use the $14M Series A to expand its commercial team, build on recent market traction, and continue development of its oncology product. The financing supports continued product development and commercial expansion.

Total raised

$47M

Funding rounds

3

Latest round

Series B

Latest activity

May 2024